Live Chat
Today's Hours: 8:00am - 10:00pm
Lane Medical Library

Search

Filter Results

Did You Mean:

Search Results

Sort by
relevance
  • Book
    Yashwant Pathak, editor.
    Summary: This book evaluates trends arising in "--Omics" sciences in terms of their current and potential future application to therapeutic design and understanding of disease. Chapters consider the impact of pharmacogenomics and bioinformatics on drug development, as well as trends in genomics, as applied to understanding of neurodegenerative and lung disease, psychiatry and oncology. Following the genome studies released in early part of this century, the advent of the -Omics sciences (genomics and pharmacogenomics, proteomics, metabolomics, transcriptomics) has seen the expansion of a vast knowledgebase with utility in preventing and treating disease, and improving health for all. Bioinformatics and improved pharmacogenetic understanding forge a path for improved drug discovery and design methods accounting for differences in delivery and disposition across populations.

    Contents:
    Intro; Foreword; Preface; Omics-Driven Trends in Disease Prevention and Better Healthcare; Contents; Contributors;
    1: Rethinking Drug Discovery and Targeting After the Genomic Revolution; 1.1 Introduction; 1.2 Genomic Revolution; 1.3 Changing Scenario in Drug Discovery and Targeting; 1.3.1 A New Pattern for Drug Development in the Form of Pharmacogenomics; 1.3.2 Personalized Medicine for Individual Genomes; 1.4 Paradigm Shift in the Treatment of Disease in the Postgenomic Era; 1.4.1 Shift in Treatment and Drug Development for Cancer 1.4.2 Shift in Treatment and Drug Development for Cardiovascular Disease1.4.3 Shift in Treatment and Drug Development for Tuberculosis; References;
    2: Living Between Sickness and Health: Where Is the Human Genome Leading Us?; 2.1 Introduction; 2.2 Cancer; 2.2.1 Lung Cancer; 2.2.2 Breast Cancer; 2.2.3 Prostate Cancer; 2.2.4 Colorectal Cancer; 2.3 Cardiovascular System; 2.3.1 Coronary Heart Disease; 2.3.2 Pulmonary Arterial Hypertension; 2.3.3 Stroke; 2.3.4 Dyslipidemia; 2.4 Mental Illness; 2.4.1 Depression/Bipolar Disorder; 2.4.2 Parkinson's Disease; 2.4.3 Alzheimer's Disease 2.4.4 SchizophreniaReferences;
    3: Pharmacogenomics: Setting Newer Paradigms of Genetics in Therapy and Medicine; 3.1 Introduction; 3.2 Pharmacogenomics: Genetic Variability and Pharmacokinetics; 3.3 Pharmacogenetics and Drug Pharmacodynamics; 3.4 Different Types of Genetic Polymorphisms and Their Impact on Pharmacotherapy; 3.4.1 Single-Nucleotide Polymorphisms (SNPs); 3.4.2 Noncoding Region Polymorphisms; 3.4.2.1 Promoter Polymorphism; 3.4.2.2 5' and 3' UTR Polymorphism; 3.4.2.3 Splice Site Polymorphism; 3.4.2.4 Short Tandem Repeat Polymorphism 3.4.2.5 Insertion/Deletion Polymorphism (Indels)3.5 Technologies of Pharmacogenomics; 3.6 Clinical Relevance of Pharmacogenomics; 3.6.1 Side Effects and Toxicity; 3.6.2 Therapeutic Efficacy; 3.7 Applications of Pharmacogenomics; 3.7.1 Pharmacogenomics: Improving Productivity of Drug Development Process; 3.7.2 Pharmacogenomics: Establishing Drug Safety; 3.7.3 Pharmacogenomics: Development of Molecular Diagnostics; 3.7.4 Pharmacogenomics: Application for Personalized Medicine; 3.8 Pharmacogenomics and Its Impact on Pharmaceutical Market; 3.8.1 Market Segmentation 3.8.2 Market Expansion3.9 Challenges of Pharmacogenomics; 3.9.1 Financing Personalized Healthcare; 3.9.2 Ethical and Legal Issues; 3.9.3 Scientific Uncertainty; 3.10 Future Prospects of Pharmacogenomics; References;
    4: Bioinformatics and Pharmacogenomics: Tools to Understand and Accelerate Infectious Disease Control; 4.1 Introduction; 4.2 Infectious Diseases Scenario in Developing Countries; 4.3 Need for Developing Bioinformatics Tools; 4.4 Clinical Bioinformatics; 4.5 Bioinformatics Tools for Population Science Study; 4.5.1 Google Trends
    Digital Access Springer 2018
  • Article
    Kwa BH, Liew FY.
    J Helminthol. 1978 Mar;52(1):1-6.
    An attempt was made to determine if blocking antibody is involved in protecting cysticerci of Taenia taeniaeformis against a host immune response. Immunoflourescence microscopy confirmed that host antibody is presnet on the parasite surface within the capsule. To test if the larvae can still survive after such a coat of blocking antibody is removed, the larvae were trysinised and then implanted into recipients. The results indicate that blocking antibody could be involved in the survival of 1 year old established larvae. Untrypsinised larvae were normal 14 days after implantation into control or immunised rats. Trypsinised larvae implanted in control rats were alive but showed on intense cell adherence on their surface. On the other hand, trypsinised larvae implanted into immunised rats were dead and completely encapsulated. However, experiments with 1 month old larvae were inconclusive.
    Digital Access Access Options